- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
126
early POAG diagnosis. At present, the optic head morphological and morphometric analysis is considered to give important clues to the early diagnosis of the disease and the follow-up of its progression. In fact, the ganglion cells death, which is responsible for the functional damage, directly affects both the optical head morphology and the RNFL thickness, thus anticipating the clinical and VF damage.
The examination of the optic nerve head and the papillary area should be simple, quick, objective, accurate, and reproducible. Recently, the new lasers based on polarimetric technique (GDx) and on confocal tomography (Heidelberg retinal tomograph, HRT) have allowed the objective and reproducible morphological and morphometric evaluation of both optic nerve head and RNFL.
The GDx scanning laser polarimeter
The GDx (Laser Diagnostic Technologies, Inc., San Diego, CA), performing a scanning laser polarimetry study of the retina, is a noninvasive diagnostic technique used to estimate the RNFL thickness using a polarized laser beam with a wavelength of 780 nm (Hollo et al., 1997; Weinreb et al., 1998; Yamada et al., 2000).
The linear birefringence property of RNFL is determined by the presence of the microtubules with a parallel disposition within the nervous fiber, inducing a variation of polarization of the light beam, which passes through them. These polarization changes, called retardation, are linearly related to the histological characteristic of the analyzed structure and can be registered by a polarization detector, giving an evaluation of the RNFL thickness.
The polarization detector measures the retardation of the light coming from the analyzed retinal point. The thickness of RNFL, obtained through an algorithm, is shown by means of color representations, in an image of 256 256 pixels that is acquired and stored in the computer memory.
The image acquisition is possible also with a miotic pupil, unless the pupillary diameter is not
lower than 2 mm, although a regular pupillary diameter is essential to perform the examination correctly (Weinreb et al., 1995).
Since other birefringent ocular tissues, such as the cornea, may interfere with the results of the test, a corneal compensator was added to allow the evaluation of the variation in birefringence due to the corneal interference, which is peculiar for each patient (Greenfield et al., 2000; Weinreb et al., 2002a). This latest version of the RNFL analyzed is named GDx-VCC (variable corneal compensator), which compensates the individual corneal birefringence hence allowing a good correction of the corneal polarization effect. In this way, a more reliable evaluation of the RNFL thickness can be achieved (Weinreb et al., 2002b; Tannenbaum et al., 2004).
Before performing the test, it is necessary to insert patients’ personal and clinical data, such as date of birth, gender, ethnicity, associated systemic disease, and spherical equivalent. Each eye will be examined on its own. The test progression is as follows.
A first scansion, called corneal compensation, is carried out on the macular region where the birefringence is assent. This measure is used to obtain the compensation of the corneal birefringence; the examiner must check the exact positioning of the ellipse corresponding to the macular region, which will appear homogeneously colored in blue (Fig. 1).
Once the corneal birefringence compensation has been carried out, the ‘‘acquisition’’ phase will take place. In this phase, it will be possible to get
Fig. 1. Image of the macular region evenly stained in blue due to the absence of the birefringence.
compensated images of the RNFL. The compensation check is carried out only once, at the first test, and the value obtained is stored in a database to be used in future examinations. It is possible that a new measurement of corneal compensation is required in case of overcoming cataract or refractive surgery. In this phase, an ellipse delimiting the optic nerve head will be shown. This ellipse can be modified in order to compensate the presence of optic nerve anomalies, such as peripapillary atrophy and scleral crescent.
During the acquisition phase, two concentric circles will be shown around the papilla. The area of calculation is included between the two circles. Three images will be automatically acquired. The final image is obtained from a mean of these three images. This image is divided into four segments centered on the optic nerve head: superior and inferior 1201 wide, nasal 701 wide, and temporal 501 wide. In this way are identified the areas from where the data are obtained and showed in the graphic representation called TSINT (temporal, superior, nasal, inferior, temporal). The measures obtained in the different areas will contribute to obtain the so-called nerve fiber index (NFI), which is supposed to reflect the probability that the patient has a glaucomatous damage on a scale from 0 to 100, where values above 40 are considered abnormal.
The area where the calculation is performed is automatically determined and is set on a minimal dimension. It extends only for 35 pixels with an inner diameter of 27 pixels and 8 pixels width (Fig. 2).
In the emmetropic eye, it is possible to have the dimensions expressed in millimeters, as they are measured on the retina: outer ray 1.628 mm and inner ray 1.256 mm. The values expressed in pixels are worked out so that 256 values, uniformly distributed along the circular area, are obtained.
Three areas of different dimensions are available for the calculation of the parameters: small, medium, and large. In Table 1 are summarized the dimensions of each variable.
In general, it is advisable to use a small calculation area because it allows better quality and more reliable results.
127
Fig. 2. Calculation area.
Table 1. Parameters of three area used for calculation
Areas |
Inner ray |
Outer ray |
Calculation |
|
|
|
rectangle |
|
|
|
|
Small |
27 pixels |
35 pixels |
88 88 pixels |
|
(1.256 mm) |
(1.628 mm) |
88 88 pixels |
Medium |
35 pixels |
43 pixels |
|
|
(1.628 mm) |
(2.0 mm) |
104 104 pixels |
Large |
43 pixels |
51 pixels |
|
|
(2.0 mm) |
(2.372 mm) |
|
|
|
|
|
In case of patients with peripapillary atrophy, myopic crescent, or other optic nerve head morphological anomalies, it is better to use larger areas because with the small one the data collected could be unreliable.
Performing the measurements, the computer calculates the light retardation from all the areas considered. The data obtained from each patient are compared with the database obtained in normal subjects of the same age. In this way are evaluated 13 indexes, which include several measurements obtained in the peripapillary region.
The results are represented in a printout (Fig. 3), where data and images, obtained for each eye, are presented separately according to two types of analysis, namely, nerve fiber analysis (NFA) and serial analysis.
128
Fig. 3. Printout of a GDx examination.
Nerve fiber analysis
The NFA includes fundus images, RFNL thickness map, TSINT parameters, NFI, TSINT graphic, and deviation from reference map.
The central TSNIT graphic shows data from both eyes in order to facilitate the evaluation of the
interocular symmetry, which is only shown in this graph.
Color image: Color has been artificially added to this image of the optic nerve head and the peripapillary retina in order to assist their
observation and to allow the evaluation of the quality of the scan performed (Fig. 4).
Thickness (polarization) map: This map gives a color-coded image of the measured points to indicate RNFL thickness. Bright colors (red and yellow) are associated with thicker areas, signifying healthy RNFL. Dark colors are associated with thinner areas, indicating less healthy RNFL. In the scheme from normal subjects, light yellow and red colors are allocated in the superior and inferior sectors, while green and blue colors are located in nasal and temporal sectors, respectively (Fig. 5).
Standard deviation map: This is a superpixel map showing different colors with respect to the probability to deviation from normal values of reference (Fig. 6).
TSNIT (double hump) graph: In TSNIT
graph are shown the normal values (shaded area) and patient values (dark line) relative to the RNFL thickness on the data obtained in the calculation area. Looking at the TSNIT graph, from left to right, are shown the thickness values of the temporal, superior, nasal, inferior, and temporal again. In normal condition, the RNFL profile shows a double hump aspect with higher thickness in the superior and inferior sectors and lower values in nasal and temporal sectors (Fig. 7).
TSNIT symmetry graph: This is a confrontation of the TSINT graphs from both eyes of the patient. In this graph, it is possible to evaluate if there are differences in the RNFL
Fig. 4. Color image of the optic nerve head and the peripapillary area.
129
Fig. 5. Thickness polarization map.
Fig. 6. Standard deviation map.
Fig. 7. TSNIT double hump graph.
130
thickness and TSNIT form and position between the two eyes.
Deviation from normal map: In this map, the RNFL thickness of the patients is compared with normative database. Small colored squares indicate the percentage of deviation from normal value in a certain evaluated point. The area from where the squares are evaluated is shown on black and white image of the ocular fundus for reference. A color legend defines the statistical significance of the devia-
tion from normal values with a significance comprised between pW5% and po0.5%.
TSNIT parameters: The data from the calculation area of the patients are matched with those from a normative database. The parameters are encoded according to different colors to indicate the deviation from normal values and can help in distinguishing between glaucomatous and normal subjects. However, these parameters should be considered together with other clinical data of the patients.
In the TSNIT table are considered the following parameters:
1.TSNIT average: It indicates the mean thickness values in the calculation area.
2.Superior average: It indicates the mean thickness of the pixels in the superior 1201.
3.Inferior average: It indicates the mean thickness of the pixels in the inferior 1201.
4.TSNIT standard deviation.
5.Inter-eye symmetry: It shows the correlation of the TSNIT data for corresponding points of both eyes. If the ratio is close to 1, the RNFL will be symmetric in both eyes.
Nerve fiber indicator: It is an indicator of the probable presence of the POAG. The GDxVCC system has an algorithm aimed to optimize the confrontation between normal and abnormal RNFL; to obtain this algorithm, images from glaucomatous and normal eyes were used.
The NFI is shown in a numeric format from 0 to 100. The higher the number, the higher is the probability that the patient is affected by glaucoma. This index is not related to the gravity or the progression of POAG.
Although there may be some exceptions, it is possible to use the following scale as a guideline for NFI evaluation:
o30, low probability of POAG 30–50, suspect of POAG
W50, high probability of POAG
The NFI depends on the good positioning of the circle, which must be centered on the optic nerve head; a modification of the circle position can interfere with the NFI value obtained.
Symmetry: This is the mean ratio between the mean of the 210 thickest measurements from the superior and inferior sectors. The closer the ratio to 1, the higher the RNFL symmetry in these sectors.
Superior ratio: This is the mean ratio between the mean of the 210 thickest measures from the superior and temporal sectors.
Inferior ratio: This is the mean ratio between the mean of the 210 thickest measures from the inferior and temporal sectors.
Superior/nasal: This is the mean ratio between the mean of the 210 thickest measures from the superior and nasal sectors.
Max modulation: It gives an indication of the differences existing between the thickest and the thinnest areas of the RNFL. The higher this number, the higher the difference between thick and thin RNFL areas. In normal eyes, where the inferior and superior RNFL thickness is higher than that of nasal and temporal, the number obtained is generally higher than 1.
Superior maximum: This is the mean of the 210 thickest measurements of the superior sector.
Inferior maximum: This is the mean of the 210 thickest measurements of the inferior sector.
Ellipse modulation: Similar to the max modulation parameters, it indicates the difference existing between the thickest and thinnest areas of RNFL. These parameters used only the points along the ellipse circumscribing the optic nerve.
